(TRNS) Transcat - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8935291075

TRNS: Calibration, Laboratory, Instruments, Services, Test, Measurement

Transcat, Inc. (NASDAQ:TRNS) is a leading provider of calibration and laboratory instrument services, operating across the United States, Canada, and internationally. The company is structured into two primary business segments: Service and Distribution, each tailored to meet the precise needs of industries where accuracy and compliance are paramount.

The Service segment is the cornerstone of Transcats operations, offering a comprehensive suite of services including calibration, repair, inspection, analytical qualification, and preventative maintenance. To enhance operational efficiency, the company has developed CalTrak, a proprietary document and asset management system. This platform streamlines workflow management for both its calibration service centers and customers assets. Additionally, Transcat provides an online customer portal known as Compliance, Control and Cost, which offers web-based asset management capabilities and secure off-site storage for calibration and service records. These tools not only improve transparency but also ensure that customers maintain regulatory compliance in their operations.

The Distribution segment focuses on the sale and rental of test, measurement, and control instruments, catering to a wide range of industries. Beyond hardware, this segment also offers value-added services such as equipment calibration and certification, rental options, used equipment sales, and equipment kitting. Transcat markets its products through a multi-channel approach, including its website, digital and print advertising, outbound sales initiatives, and an inbound call center. This diversified strategy ensures that customers have easy access to the tools they need to maintain precision and efficiency in their processes.

Transcats customer base spans highly regulated industries, with a significant focus on life sciences, including pharmaceutical, biotechnology, medical device, and other FDA-regulated sectors. The company also serves aerospace and defense, industrial manufacturing, energy and utilities, and other industries where the accuracy of equipment and processes is critical. By providing specialized services and products, Transcat plays a pivotal role in ensuring that its customers meet stringent regulatory requirements and maintain operational excellence.

Founded in 1964 and headquartered in Rochester, New York, Transcat has established itself as a trusted partner for industries requiring precision and reliability. Its commitment to innovation and customer satisfaction has positioned it as a key player in the calibration and instrument

Additional Sources for TRNS Stock

TRNS Stock Overview

Market Cap in USD 683m
Sector Industrials
Industry Industrial Distribution
GiC Sub-Industry Trading Companies & Distributors
IPO / Inception 1990-03-27

TRNS Stock Ratings

Growth 5y 51.1%
Fundamental 25.2%
Dividend 0.0%
Rel. Strength -36.3
Analysts 4.4/5
Fair Price Momentum 69.51 USD
Fair Price DCF 48.16 USD

TRNS Dividends

No Dividends Paid

TRNS Growth Ratios

Growth Correlation 3m -86.8%
Growth Correlation 12m -68.8%
Growth Correlation 5y 87%
CAGR 5y 23.34%
CAGR/Max DD 5y 0.45
Sharpe Ratio 12m -0.07
Alpha -38.05
Beta 0.661
Volatility 48.06%
Current Volume 74.1k
Average Volume 20d 61.8k
What is the price of TRNS stocks?
As of April 03, 2025, the stock is trading at USD 75.36 with a total of 74,123 shares traded.
Over the past week, the price has changed by +4.89%, over one month by +0.09%, over three months by -28.95% and over the past year by -30.86%.
Is Transcat a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Transcat is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.24 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TRNS as of April 2025 is 69.51. This means that TRNS is currently overvalued and has a potential downside of -7.76%.
Is TRNS a buy, sell or hold?
Transcat has received a consensus analysts rating of 4.40. Therefor, it is recommend to buy TRNS.
  • Strong Buy: 3
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for TRNS stock price target?
According to ValueRays Forecast Model, TRNS Transcat will be worth about 77 in April 2026. The stock is currently trading at 75.36. This means that the stock has a potential upside of +2.23%.
Issuer Forecast Upside
Wallstreet Target Price 100.2 32.9%
Analysts Target Price 121.2 60.8%
ValueRay Target Price 77 2.2%